|
Apr 16
|
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
|
|
Dec 7
|
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
|
|
Sep 5
|
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
|
|
Sep 5
|
Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
|